The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of
schizophrenia. Both were initially based on indirect evidence from pharmacological studies …

Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D 2-type
dopamine receptors. Given the limitations of these medications, substantial efforts have …

The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-
aspartate glutamate receptor antagonist, have not been fully elucidated. This study …

Objective: Whilst dopaminergic dysfunction remains a necessary component involved in the
pathogenesis of schizophrenia, our current pharmacological armoury of dopamine …

Glutamatergic transmission in schizophrenia: from basic rese... : Current Opinion in Psychiatry
Glutamatergic transmission in schizophrenia: from basic research to clinical practice : Current …

The early developments of brain positron emission tomography (PET), including the
methodological advances that have driven progress, are outlined. The considerable past …

Background Preclinical and postmortem studies have implicated the metabotropic glutamate
receptor 5 (mGluR5) in the pathophysiology of major depressive disorder (MDD). The goal …

Nicotine addiction is a major public health problem, resulting in primary glutamatergic
dysfunction. We measured the glutamate receptor binding in the human brain and provided …

Molecular imaging with positron emission tomography (PET) and single photon emission
computed tomography (SPECT) is a well-established and important in vivo technique to …

Background At subanesthetic doses, ketamine, an N-methyl-D-aspartate glutamate receptor
antagonist, increases glutamate release. We imaged the acute effect of ketamine on brain …